CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/initial-btk-inhibitor-based-treatment-selection-in-a-treatment-naive-symptomatic-unfit-older-patient-with-comorbidities-and-high-risk-cytogenetics/24452/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizi…

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences betwe…

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/selection-of-btk-inhibitor-following-frontline-chemoimmunotherapy-in-older-patients-with-comorbidities/24453/ Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-g…

CME credits: 0.25 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-cm-management-pearls-from-recent-clinical-trials-and-tailoring-therapy/18005/ Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to t…

CME credits: 0.50 Valid until: 09-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimal-sequencing-of-adcs-in-endocrine-refractory-hrher2-metastatic-breast-cancer/18104/ The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast ca…

CME credits: 1.00 Valid until: 06-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/are-two-pathways-better-than-one-experts-discuss-the-role-of-ang2-vegfa-inhibition-in-retinal-vascular-disease/16620/ Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of re…

CME credits: 1.00 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/ There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitabl…

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They d…

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic …

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell car…

CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck sq…

CME credits: 0.25 Valid until: 29-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-and-addressing-racial-disparities-in-patients-with-hrher2-early-breast-cancer-a-case-based-learning-lab/16199/ The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patien…

CME credits: 0.25 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/making-the-case-for-dual-ang-2vegf-a-inhibition-anatomical-benefits/18009/ What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker …

CME credits: 0.50 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-the-pioneer-af-pci-trial/24404/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to up…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/tools-of-the-trade-measurement-based-care-for-cias/20295/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/20297/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/not-all-therapy-needs-to-be-swallowed-or-injected-the-future-of-digital-therapeutics-to-alleviate-the-negative-symptoms-of-schizophrenia/20300/ This series of bite-sized episodes will provide important information on cognitive impairment associated w…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/unraveling-the-overlapping-negative-and-cognitive-symptoms-in-schizophrenia/20294/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig di…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/challenges-of-integrating-cognitive-remediation-in-cias/20296/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysi…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/cias-effects-on-patients-and-caregivers-what-is-the-personal-and-economic-burden-caused-by-cias/20293/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/understanding-cias-what-does-current-literature-say-about-the-etiology-and-pathophysiology-of-cias/20291/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey …

CME credits: 0.50 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-whats-really-new-in-electrophysiology-that-will-change-my-practice/24405/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical tr…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/glycines-role-in-driving-the-cognitive-symptoms-of-cias/20292/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysi…

CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/staying-current-what-do-recent-clinical-trial-data-say-about-the-new-and-emerging-treatment-options-for-cias/20298/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Phil…

CME credits: 0.50 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-voyager-pad-part-1/24406/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates …